Editas Medicine Common Stock share price logo

Editas Medicine Common Stock

NASDAQ: EDIT

Small Cap

$2.81

+0.06

(+1.99%)

Live

as on

Editas Medicine Common Stock Stock Performance

as on June 25, 2026 at 4:27 am IST

  • Day's Low

    Day's High

    $2.75
    $2.96
    downward going graph

    2.14%

    Downside

    5.34%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.66
    $4.54
    downward going graph

    40.93%

    Downside

    61.47%

    Upside

    downward going graph

Editas Medicine Common Stock share price movements today

Previous Close
$2.76
Open
$2.80
Volume
2.6M
Day's Low - High
$2.75 - $2.96
52 Week Low - High
$1.66 - $4.54

Editas Medicine Common Stock Historical Returns

1 Month Return
0 %
3 Month Return
+ 22.67 %
1 Year Return
+ 22.67 %
3 Year Return
-65.8 %
5 Year Return
-93.25 %

Editas Medicine Common Stock Stock Fundamentals & Key Indicators

Check Editas Medicine Common Stock market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$440.4M

EPS (TTM)

-0.9961

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-85.2M

Revenue (TTM)

38.7M

Profit Margin

-281.59%

Return On Equity TTM

-326.07%

Editas Medicine Common Stock vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Editas Medicine Common Stock with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$440.4M-93.25%NA-281.59%NA
BUY$38.2B65.93%71.9612.55%NA
BUY$118.5B144.05%27.735.51%NA
BUY$64.2B13.51%14.9529.65%0.59%

Stock Returns calculator for Editas Medicine Common Stock Stock including INR - Dollar returns

The Editas Medicine Common Stock stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Editas Medicine Common Stock investment value today

Current value as on today

₹1,37,563

Returns

₹37,563

(+37.56%)

Returns from Editas Medicine Common Stock Stock

₹24,889 (+24.89%)

Dollar Impact

₹12,674 (+12.67%)

Analyst Recommendation on Editas Medicine Common Stock Stock

Based on 24 analysts

BUY

54.17%

Buy

41.67%

Hold

4.17%

Sell

Based on 24 analysts, 54.17% of analysts recommend a 'BUY' rating for Editas Medicine Common Stock. Average target price of $5.78

Editas Medicine Common Stock Share Price Target

Get share price movements and forecasts by analysts on Editas Medicine Common Stock.

What analysts predicted

51.38%UPSIDE

Target Price

$5.78

Current Price

$2.81

Analyzed by

24 Analysts

Target

$5.78

Editas Medicine Common Stock target price $5.78, a slight upside of 51.38% compared to current price of $2.81. According to 24 analysts rating.

Indian Investors' Interest in Editas Medicine Common Stock Stock

Search interest for Editas Medicine Common Stock Stock has increased by 58% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:58% versus previous 30 day period

Editas Medicine Common Stock Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
60
1
0
0
30
4
3
7
24
2
Gross Profit
58
0
0
-1
-18
-21
-12
-12
24
2
Operating Income
-23
-66
-71
-65
-46
-76
-51
-24
-14
-25
EBITDA
-17
-60
-66
-60
-32
-71
-49
-21
-5
-23
Interest Expense
3
-
-
-
-
2
2
2
6
1
Depreciation
1
1
1
1
1
1
1
0
0
0
Income Before Tax
-18
-61
-67
-62
-45
-76
-53
-25
-5
-24
Income Tax Expense
10
0
-
1
-
-
-
-
-
-
Net Income
-18
-61
-67
-62
-45
-76
-53
-25
-5
-24
Net Profit Margin
-31.43%
-5458.15%
-13178.75%
-101870.49%
-148.33%
-1633.49%
-1487.84%
-332.98%
-22.72%
-882.44%

Editas Medicine Common Stock Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
6
13
31
20
90
25
19
78
32
40
Gross Profit
-50
-69
-58
-76
90
25
19
72
-166
40
Operating Income
-97
-119
-113
-140
-134
-193
-225
-169
-251
-99
EBITDA
-96
-116
-110
-138
-130
-188
-219
-147
-233
-148
Interest Expense
0
0
3
7
2
5
4
-
2
6
Depreciation
-
2
3
2
3
5
6
6
5
5
Income Before Tax
-97
-120
-109
-133
-115
-192
-220
-153
-237
-160
Income Tax Expense
-1
-1
-3
-10
-6
-7
-16
5
-
-
Net Income
-97
-120
-109
-133
-109
-185
-204
-153
-237
-160
Net Profit Margin
-1605.53%
-876.49%
-344.28%
-651.43%
-120.59%
-724.66%
-1036.69%
-196.13%
-733.72%
-395.01%

Editas Medicine Common Stock Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-61
-67
-62
-45
-76
-53
-25
-5
-24
Operating Cash Flow
-49
-57
-52
-50
-47
-50
-30
-36
-23
Investing Cash Flow
-4
51
83
30
56
42
39
0
0
Financing Cash Flow
0
0
-
55
-1
7
17
17
-
Change in Cash
-54
-4
31
35
7
0
25
-19
-22

Editas Medicine Common Stock Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-120
-109
-133
-115
-192
-220
-153
-237
-160
Operating Cash Flow
-9
-45
-40
-179
-163
-177
-132
-210
-165
Investing Cash Flow
-183
-53
12
-140
-54
114
-3
162
138
Financing Cash Flow
154
86
131
224
282
1
118
56
40
Change in Cash
-38
-11
103
-96
63
-61
-17
7
13

Global Institutional Holdings in Editas Medicine Common Stock

Funds
Holdings
Kennedy Capital Management Inc
0.69%
BlackRock Inc
6.04%
Vanguard Capital Management, LLC
2.74%
The Goldman Sachs Group Inc
0.57%
Susquehanna International Group, LLP
0.72%

Insights on Editas Medicine Common Stock

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, EDIT stock has moved up by 8.2%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, EDIT has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Editas Medicine, Inc. Common Stock has experienced a drawdown of -65.8%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 45.1%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 24.74M → 2.83M (in $), with an average decrease of 88.6% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -5.62M → -24.98M (in $), with an average decrease of 344.5% per quarter

About Editas Medicine Common Stock

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
OrganisationEditas Medicine Common Stock
Headquarters11 Hurley Street, Cambridge, MA, United States, 02141
IndustryBiotechnology
CEODr. Gilmore O'Neill M.D.
E-voting on sharesClick here to vote

Key Management of Editas Medicine Common Stock

Name

Title

Dr. Gilmore O'Neill M.D.

President, CEO & Director

Dr. Linda C. Burkly Ph.D.

Executive VP & Chief Scientific Officer

Dr. Feng Zhang Ph.D.

Co-Founder & Scientific Advisory Board Member

Mr. Tom Love

Vice President of People

Mr. Frank Panaccio

Senior VP & Chief Business Officer

Ms. Brieana Buckley

Senior Vice President of Development and Program Leadership

Ms. Amy Parison

Senior VP & CFO

Dr. George McDonald Church Ph.D.

Co-Founder & Scientific Advisory Board Member

Mr. Gregory Whitehead

Executive VP and Chief Technical & Quality Officer

Mr. Damien Grierson J.D.

Senior VP, General Counsel & Corporate Secretary

FAQs

What is Editas Medicine Common Stock share price today?

Editas Medicine Common Stock share price today is $2.81 as on . Editas Medicine Common Stock share today touched a day high of $2.96 and a low of $2.75.

What is the 52 week high and 52 week low for Editas Medicine Common Stock share?

Editas Medicine Common Stock share touched a 52 week high of $4.54 on and a 52 week low of $1.66 on . Editas Medicine Common Stock stock price today i.e. is trending at $2.81,which is 38.07% down from its 52 week high and 69.28% up from its 52 week low.

What is Editas Medicine Common Stock's market capitalisation today?

Editas Medicine Common Stock market capitalisation is $0.00T as on .

How to invest in Editas Medicine Common Stock Stock (EDIT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Editas Medicine Common Stock on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Editas Medicine Common Stock Shares that will get you 0.5338 shares as per Editas Medicine Common Stock share price of $2.81 per share as on June 24, 2026 at 10:57 pm IST.

What is the minimum amount required to buy Editas Medicine Common Stock Stock (EDIT) from India?

Indian investors can start investing in Editas Medicine Common Stock (EDIT) shares with as little as ₹94.665 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.65 in Editas Medicine Common Stock stock (as per the Rupee-Dollar exchange rate as on ). Based on Editas Medicine Common Stock share’s latest price of $2.81 as on June 24, 2026 at 10:57 pm IST, you will get 3.5587 shares of Editas Medicine Common Stock. Learn more about fractional shares .

What are the returns that Editas Medicine Common Stock has given to Indian investors in the last 5 years?

Editas Medicine Common Stock stock has given -93.25% share price returns and 27.62% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?